Overview
Converge Bio, an AI platform aimed at accelerating drug discovery and development, has raised $25 million in Series A funding, totaling $30 million in capital raised. The round was led by Bessemer Venture Partners, with participation from TLV Partners, Vintage Investment Partners, and Saras Capital, along with individual executives from Meta, OpenAI, and Wiz.
Products
Loading...
Recent Deals
Investors: Bessemer Venture Partners, TLV Partners, Vintage Investment Partners, Saras Capital
Converge Bio, an AI platform aimed at accelerating drug discovery and development, has raised $25 million in Series A funding, totaling $30 million in capital raised. The round was led by Bessemer Venture Partners, with participation from TLV Partners, Vintage Investment Partners, and Saras Capital, along with individual executives from Meta, OpenAI, and Wiz.